These very encouraging results from DESTINY-Lung01 have rapidly motivated the setup of a randomized, open-label, phase III trial (DESTINY-Lung04; NCT05048797) to evaluate the efficacy and safety of T-Dxd compared to the standard of care (pembrolizumab combined with chemotherapy) in patients with non-squamous NSCLC harboring a HER2 exon 19 or 20 mutation. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.